Zoetis Inc. (ZTS)
ZTS stock forecast: what analysts expect
Wall Street analysts covering Zoetis Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $100.94 — +37.3% versus the last price of $73.54. Targets reflect analyst opinion, not a guarantee.
ZTS historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in ZTS.
ZTS annual returns by year
Congress trading in ZTS
21 members of Congress have disclosed trading ZTS — 20 purchases and 17 sales worth an estimated $418,500. Most recent disclosure: Jun 16, 2026.
See who in Congress traded ZTS →About Zoetis Inc.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.
ZTS Key Statistics
ZTS in plain English
- P/E ratio (12.3) — how many dollars you pay for each $1 of ZTS's yearly profit. That's on the low side, which can mean it's cheap — or that the market is worried.
- ROE (64.91%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (27.68%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (2.81%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
ZTS stock: frequently asked questions
What is Zoetis Inc.'s stock price today?
Zoetis Inc. (ZTS) last traded at $73.54 on the NYSE. Over the past 52 weeks the stock has traded between $71.45 and $160.48.
Is ZTS stock a buy or a sell?
Wall Street analysts' consensus rating on ZTS is "Buy", with an average 12-month price target of $100.94 — about +37.3% versus the current price of $73.54. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in ZTS 10 years ago be worth today?
A $1,000 investment in Zoetis Inc. made 10 years ago would be worth about $1,571 today (dividends reinvested) — a total return of 57%, or 4.6% per year.
Does ZTS pay a dividend?
Yes. Zoetis Inc. currently pays a dividend yielding about 2.81% per year at today's share price.
What is ZTS's P/E ratio?
ZTS trades at a trailing price-to-earnings ratio of 12.3, and 10.9 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade ZTS stock?
Yes — 21 members of Congress have disclosed trades in ZTS under the STOCK Act, totaling 20 purchases and 17 sales worth an estimated $418,500.
What is Zoetis Inc.'s ticker symbol?
Zoetis Inc. trades under the ticker symbol ZTS on the NYSE.
Compare ZTS with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.